Mucosal melanomas (MMs) are under-researched tumors with a poor prognosis that arise from melanocytes found in the mucous membranes at different anatomical locations throughout the body. MMs are an uncommon yet highly aggressive tumor that typically develops on mucosal surfaces, predominantly in the head and neck region. MM of the head and neck occurs in 8–10% of all head and neck melanomas. It most commonly affects the mucosa of the nasal cavity and paranasal sinuses (75%), followed by the oral cavity mucosa (25%). A family history and the presence of mucosal nevi are associated with the occurrence of MM. Inhaled and dietary carcinogens are also linked to the development of sinonasal melanoma, much like other malignancies of the nasal cavity. Overexpression of the C-KIT gene is found in more than 80% of all primary mucosal melanomas, with somatic mutations in 10–30% of cases. The presence of these genetic alterations is also reflected in recent clinical studies of specific gene inhibitors that have proven efficiency in the systemic therapy of melanoma. There are various treatment modalities for MM. Surgical therapy involves en bloc surgical resection with a macroscopically visible and palpable mucosal margin of 1.5–2 cm. Partial resection of the maxilla may be considered if it ensures adequate tumor-free margine. Because of its rarity, outcome data for locally advanced head and neck MM is limited and primarily derived from retrospective studies with small case numbers. This review aims to update and summarize findings from clinical trials, prospective observational studies, and retrospective studies, while also exploring future directions for multimodal treatment approaches in this area.
Although not regarded as an oncogenic pathogen, the human cytomegalovirus (HCMV) has been associated with a wide array of malignancies. Conversely, a number of studies report on possible anti-tumor properties of the virus, apparently mediated via HCMV-galvanized T-cell tumor killing; these were recently being investigated in clinical trials for the purposes of anti-cancer treatment by means of dendritic cell vaccines and HCMV-specific cytotoxic T cells. In the present study, we have analyzed the relation between a complement of head-and-neck tumors and HCMV infection across 73 countries worldwide using Spearman correlation, univariate and multivariate regression analysis. Intriguingly, HCMV was found to be pro-oncogenic in patients with nasopharyngeal carcinoma; contrarywise, the virus manifested an inverse (i.e., anti-tumor) association with the tumors of the lip/oral region and the salivary glands. Although this putative protective effect was noted initially for thyroid neoplasia and hypopharyngeal tumors as well, after multivariate regression analysis the connection did not hold. There was no association between laryngeal cancer and HCMV infection. It would appear that, depending on the tissue, HCMV may exert both protective and oncogenic effects. The globally observed protective feature of the virus could potentially be utilized in future therapeutic approaches for salivary tumors and neoplasia in the lip/oral region. As correlation does not necessarily imply causation, more in-depth molecular analyses from comprehensive clinical studies are warranted to substantiate our findings.
Introduction: While not considered a genuine tumorigenic pathogen, the human cytomegalovirus (CMV) has been associated with a wide assortment of malignancies, including breast cancer (BC). In recent years, increasing evidence has been detailing the potential anti-oncogenic capabilities of CMV. Works in the literature addressing the issue are scarce, and a global approach elucidating the role of CMV in breast cancer is lacking. Aim: We inquired into the association between CMV and BC on a global level and surveyed the related literature. Material and Methods: Virus–tumor interaction was examined by correlating country-specific CMV seroprevalence and the age-standardized BC incidence rates for 73 countries, as provided by the International Agency for Research on Cancer (IARC). Statistical analysis was conducted using Spearman’s correlation, along with univariate and multivariate linear regression analysis. The literature review included works available in the PubMed® database until and including February 2025. Results: The worldwide incidence of BC correlated strongly and inversely with CMV prevalence the world over (p < 0.001, Spearman ρ = −0.553). This association was upheld after univariate and multivariate linear regression, extending to other tumors such as skin melanoma and kidney cancer (p < 0.001). Conclusions: In this study, we draw attention to a previously unexplored global inverse relationship between the prevalence of CMV and the incidence of BC, which suggests a potential oncoprotective role for this pathogen. Although the association itself does not imply causality, these data provide an intriguing possibility of observing CMV as a tentative factor of protection against this malignancy.